HRTX · Heron Therapeutics, Inc. · Exempt Offerings
$0.27
+0.01 (+2.23%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Nov 9, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If the payment of the debt is accelerated, absent any additional funding, cash flows from our operations will be insufficient to repay such debt in full. Therefore, if all outstanding amounts under the Working Capital Facility Agreement are accelerated, management expects there will be substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Nov 9, 2026
Market Cap
$50.25M
Shares
190.27M
Volume · Nov 19
3.61M
Avg daily vol (3M)
4.54M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
Key facts
CIK
818033
CUSIP
427746102
13F (30d)
157 filings
141 filers
Visit website
Investor relations